Last reviewed · How we verify
Atezolizumab(Tecentriq)
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on the immune system to attack cancer.
Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on the immune system to attack cancer. Used for Metastatic non-small cell lung cancer (NSCLC), Metastatic urothelial carcinoma, Metastatic triple-negative breast cancer.
At a glance
| Generic name | Atezolizumab(Tecentriq) |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Atezolizumab binds to programmed death ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors on T cells. This blockade restores anti-tumor immune responses by allowing T cells to recognize and eliminate cancer cells. It is used across multiple cancer types where PD-L1 expression correlates with response.
Approved indications
- Metastatic non-small cell lung cancer (NSCLC)
- Metastatic urothelial carcinoma
- Metastatic triple-negative breast cancer
- Hepatocellular carcinoma
- Small cell lung cancer
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Cough
- Dyspnea
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
Key clinical trials
- A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
- Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients (PHASE2)
- Iadademstat + SBRT With Atezo in ES-SCLC (PHASE1)
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung (PHASE2, PHASE3)
- A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
- A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atezolizumab(Tecentriq) CI brief — competitive landscape report
- Atezolizumab(Tecentriq) updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI